Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 50 Carcinoma, Non-Small-Cell Lung 12 Neoplasms 11 Neoplasm Metastasis 10 Carcinoma, Renal Cell 7 Skin Neoplasms 5 Prostatic Neoplasms 4 Ovarian Neoplasms 4 Lung Neoplasms 4 Glioblastoma 4 Diabetes Mellitus, Insulin-Dependent, 12 4 Carcinoma, Hepatocellular 4 Brain Neoplasms 4 Advanced Cancer 4 Uveal Melanoma 3 Triple Negative Breast Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Small Cell Lung Carcinoma 3 Recurrence 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Pancreatic Neoplasms 3 Multiple Myeloma 3 Lymphoma, Non-Hodgkin 3 Lymphoma 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Breast Neoplasms 3 Waldenstrom Macroglobulinemia 2 Sarcoma 2 Myeloproliferative Disorders 2 Lymphoma, Mantle-Cell 2

Interventions

Nivolumab 1 Ipilimumab 1 Chemoradiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Inoperable œsophageal Cancer × Ipilimumab × Clear all

NCT03437200 2023-02-21

CRUCIAL

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Terminated

Inoperable œsophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡